Cubist Systematic Strategies’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-13,460
| Closed | -$66K | – | 3759 |
|
|
2021
Q3 | $66K | Sell |
13,460
-900
| -6% | -$4.37K | ﹤0.01% | 2808 |
|
|
2021
Q2 | $76K | Buy |
+14,360
| New | +$74.3K | ﹤0.01% | 2748 |
|
|
2019
Q2 | – | Sell |
-6,148
| Closed | -$44K | – | 2653 |
|
|
2019
Q1 | $44K | Buy |
+6,148
| New | +$55.3K | ﹤0.01% | 2122 |
|
|
2017
Q4 | – | Sell |
-1,300
| Closed | -$28K | – | 2168 |
|
|
2017
Q3 | $28K | Sell |
1,300
-2,100
| -62% | -$38.5K | ﹤0.01% | 1766 |
|
|
2017
Q2 | $59K | Buy |
+3,400
| New | +$56.2K | ﹤0.01% | 1526 |
|
|
2016
Q4 | – | Sell |
-146
| Closed | -$2K | – | 1956 |
|
|
2016
Q3 | $2K | Sell |
146
-1,081
| -88% | -$16.4K | ﹤0.01% | 1668 |
|
|
2016
Q2 | $19K | Buy |
+1,227
| New | +$20.2K | ﹤0.01% | 1641 |
|
|
2015
Q3 | – | Sell |
-16,365
| Closed | -$429K | – | 2076 |
|
|
2015
Q2 | $429K | Buy |
+16,365
| New | +$318K | 0.02% | 1035 |
|
|
2015
Q1 | – | Sell |
-17,415
| Closed | -$302K | – | 2149 |
|
|
2014
Q4 | $302K | Buy |
+17,415
| New | +$264K | 0.02% | 1219 |
|
Cubist Systematic Strategies's ADMS Position: Q4 2021 in Review
Cubist Systematic Strategies sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 13,460 shares — an estimated $66K sold.
Cubist Systematic Strategies first reported a position in ADMS in Q4 2014 and held it in 9 quarters. The position peaked at $429K in Q2 2015. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Cubist Systematic Strategies reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Cubist Systematic Strategies sold 13,460 Adamas Pharmaceuticals shares in Q4 2021, an estimated $66K.
- Cubist Systematic Strategies first reported a position in Adamas Pharmaceuticals in Q4 2014 and held it in 9 quarters.
- Cubist Systematic Strategies's Adamas Pharmaceuticals position peaked at $429K in Q2 2015.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Cubist Systematic Strategies's 13F filing for Q4 2021, filed 14 Feb 2022.